Moreno J, Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol. 2002;18:399–405.
Article
PubMed
Google Scholar
Paltrinieri S, Solano-Gallego L, Fondati A, Lubas G, Gradoni L, Castagnaro M, et al. Guidelines for diagnosis and clinical classification of leishmaniasis in dogs. J Am Vet Med Assoc. 2010;236:1184–91.
Article
PubMed
Google Scholar
Athanasiou LV, Kontos VI, Saridomichelakis MN, Rallis TS, Diakou A. A cross-sectional sero-epidemiological study of canine leishmaniasis in Greek mainland. Acta Trop. 2012;122:291–5.
Article
CAS
PubMed
Google Scholar
Mendoza-Roldan J, Benelli G, Panarese R, Furlanello T, Beugnet F, Zatelli A, et al. Leishmania infantum and Dirofilaria immitis infections in Italy, 2009–2019: changing distribution patterns. Parasit Vectors. 2020;13:193.
Article
PubMed
PubMed Central
Google Scholar
Pennisi MG. Leishmaniosis of companion animals in Europe: an update. Vet Parasitol. 2015;208:35–47.
Article
PubMed
Google Scholar
Hosein S, Blake DP, Solano-Gallego L. Insights on adaptive and innate immunity in canine leishmaniosis. Parasitology. 2017;144:95–115.
Article
PubMed
Google Scholar
Day MJ. Immunopathological mechanism. In: Day MJ, editor. Clinical immunology of the dog and cat. Iowa State University Press: Iowa; 1999. p. 47–58.
Google Scholar
Day MJ. The immunopathology of canine vector-borne diseases. Parasit Vectors. 2011;4:48.
Article
PubMed
PubMed Central
Google Scholar
Parody N, Cacheiro-Llaguno C, Osuna C, Renshaw-Calderón A, Alonso C, Carnés J. Circulating immune complexes levels correlate with the progression of canine leishmaniosis in naturally infected dogs. Vet Parasitol. 2019;274:108921.
Article
PubMed
Google Scholar
Gizzarelli M, Fiorentino E, Ben Fayala NEH, Montagnaro S, Torras R, Gradoni L, et al. Assessment of circulating immune complexes during natural and experimental canine leishmaniasis. Front Vet Sci. 2020;7:273.
Article
PubMed
PubMed Central
Google Scholar
Zatelli A, Borgarelli M, Santilli R, Bonfanti U, Nigrisoli E, Zanatta R, et al. Glomerular lesions in dogs infected with Leishmania organisms. Am J Vet Res. 2003;64:558–61.
Article
PubMed
Google Scholar
Roura X, Cortadellas O, Day MJ, Benali SL, Canine Leishmaniosis Working Group, Zatelli A. Canine leishmaniosis and kidney disease: Q&A for an overall management in clinical practice. J Small Anim Pract. 2021;62:3.
Oliva G, Roura X, Crotti A, Maroli M, Castagnaro M, Gradoni L, et al. Guidelines for treatment of leishmaniasis in dogs. J Am Vet Med Assoc. 2010;236:1192–8.
Article
CAS
PubMed
Google Scholar
Solano-Gallego L, Miró G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L, et al. LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors. 2011;4:86.
Article
PubMed
PubMed Central
Google Scholar
European Scientific Counsel Companion Animal Parasites (ESCCAP). 5. Control of Vector-borne diseases in dogs and cats. ESCCAP Guideline 05, third edition. 2019. https://www.esccap.org/uploads/docs/t2kkcbgl_0775_ESCCAP_Guideline_GL5_v9_1p.pdf. Accessed 30 July 2021.
Baneth G, Shaw SE. Chemotherapy of canine leishmaniosis. Vet Parasitol. 2002;106:315–24.
Article
CAS
PubMed
Google Scholar
Ciaramella P, Corona M. Canine leishmaniasis: clinical and diagnostic aspects. Compendium on Continuing Education for the Practising Veterinarian North American Edition 2003;25:358–69.
Ribeiro RR, Michalick MSM, da Silva ME, Dos Santos CCP, Frézard FJG, da Silva SM. Canine leishmaniasis: an overview of the current status and strategies for control. Biomed Res Int. 2018;2018:3296893.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gómez-Ochoa P, Castillo JA, Gascón M, Zarate JJ, Alvarez F, Couto CG. Use of domperidone in the treatment of canine visceral leishmaniasis: a clinical trial. Vet J. 2009;179:259–63.
Article
PubMed
CAS
Google Scholar
Gómez-Ochoa P, Sabate D, Homedes J, Ferrer L. Use of the nitroblue tetrazolium reduction test for the evaluation of Domperidone effects on the neutrophilic function of healthy dogs. Vet Immunol Immunopathol. 2012;146:97–9.
Article
PubMed
CAS
Google Scholar
Roatt BM, Aguiar-Soares RD, Coura-Vital W, Ker HG, Moreira ND, Vitoriano-Souza J, et al. Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease. Front Immunol. 2014;5:272.
Article
PubMed
PubMed Central
CAS
Google Scholar
Segarra S, Miró G, Montoya A, Pardo-Marín L, Boqué N, Ferrer L, et al. Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis. Vet Parasitol. 2017;239:50–6.
Article
CAS
PubMed
Google Scholar
Segarra S, Miró G, Montoya A, Pardo-Marín L, Teichenné J, Ferrer L, et al. Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound. Parasit Vectors. 2018;11:103.
Article
PubMed
PubMed Central
CAS
Google Scholar
Baxarias M, Martínez-Orellana P, Baneth G, Solano-Gallego L. Immunotherapy in clinical canine leishmaniosis: a comparative update. Res Vet Sci. 2019;125:218–26.
Article
CAS
PubMed
Google Scholar
Gonçalves AAM, Leite JC, Resende LA, Mariano RMDS, Silveira P, Melo-Júnior OAO, et al. An overview of immunotherapeutic approaches against canine visceral leishmaniasis: what has been tested on dogs and a new perspective on improving treatment efficacy. Front Cell Infect Microbiol. 2019;9:427.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fernandez M, Tabar MD, Arcas A, Mateu C, Homedes J, Roura X. Comparison of efficacy and safety of preventive measures used against canine leishmaniasis in southern European countries: longitudinal retrospective study in 1647 client-owned dogs (2012–2016). Vet Parasitol. 2018;263:10–7.
Article
PubMed
Google Scholar
Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33:429–40.
Article
CAS
PubMed
Google Scholar
Siragy HM, Felder RA, Howell NL, Chevalier RL, Peach MJ, Carey RM. Evidence that dopamine-2 mechanisms control renal function. Am J Physiol. 1990;259:F793-800.
CAS
PubMed
Google Scholar
Siragy HM, Felder RA, Peach MJ, Carey RM. Intrarenal DA2 dopamine receptor stimulation in the conscious dog. Am J Physiol. 1992;262:F932–8.
CAS
PubMed
Google Scholar
Paltrinieri S, Ibba F, Barbè F, Rossi G. Influence of domperidone supplementation on short-term changes in C-reactive protein and paraoxonase-1 in dogs with leishmaniasis undergoing meglumine antimoniate and allopurinol therapy. Vet Clin Pathol. 2020;49:618–23.
Article
PubMed
Google Scholar
IRIS (International Renal Interest Society). 2019. IRIS staging of CKD (modified 2019). http://www.iris-kidney.com/pdf/IRIS_Staging_of_CKD_modified_2019.pdf. Accessed 30 July 2021.
IRIS (International Renal Interest Society). 2019. Treatment recommendations for CKD in dogs. http://www.iris-kidney.com/pdf/IRIS-DOG-Treatment_Recommendations_2019.pdf. Accessed 30 July 2021.
Beatrice L, Nizi F, Callegari D, Paltrinieri S, Zini E, D’Ippolito P, et al. Comparison of urine protein-to-creatinine ratio in urine samples collected by cystocentesis versus free catch in dogs. J Am Vet Med Assoc. 2010;236:1221–4.
Article
CAS
PubMed
Google Scholar
Boarino A, Bollo E, Prunotto L, Canale L, Uslenghi F, Poletti P. Application of a recombinant protein for the serological diagnosis of canine leishmaniasis. Comp Immunol Microbiol Infect Dis. 2008;31:527–36.
Article
CAS
PubMed
Google Scholar
Travi BL, Miró G. Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications. Mem Inst Oswaldo Cruz. 2018;113:e180301.
Article
CAS
PubMed
PubMed Central
Google Scholar
Reis AB, Martins-Filho OA, Teixeira-Carvalho A, Carvalho MG, Mayrink W, Franca-Silva JC, et al. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet Sci. 2006;81:68–75.
Article
CAS
PubMed
Google Scholar
Berczi I, Bertok L, Chow DA. Natural immunity and neuroimmune host defense. Ann N Y Acad Sci. 2000;917:248–57.
Article
CAS
PubMed
Google Scholar
Hinterberger-Fischer M. Prolactin as pro-inflammatory cytokine considerations on consolidated immunotherapy after high dosage therapy. Acta Med Austriaca Suppl. 2000;27:16–20.
Google Scholar
Di Carlo R, Meli R, Galdiero M, Nuzzo I, Bentivoglio C, Carratelli CR. Prolactin protection against lethal effects of Salmonella typhimurium. Life Sci. 1993;53:981–9.
Article
PubMed
Google Scholar
Richards SM, Garman RD, Keyes L, Kavanagh B, McPherson JM. Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas. Cell Immunol. 1998;184:85–91.
Article
CAS
PubMed
Google Scholar
Majumder B, Biswas R, Chattopadhyay U. Prolactin regulates antitumor immune response through induction of tumoricidal macrophagesandrelease of IL-12. Int J Cancer. 2002;97:493–500.
Article
CAS
PubMed
Google Scholar
Tarallo VD, Dantas-Torres F, Lia RP, Otranto D. Phlebotomine sand fly population dynamics in a leishmaniasis endemic peri-urban area in southern Italy. Acta Trop. 2010;116:227–34.
Article
PubMed
Google Scholar
Cavalera MA, Iatta R, Panarese R, Mendoza-Roldan JA, Gernone F, Otranto D, et al. Seasonal variation in canine anti-Leishmania infantum antibody titres. Vet J. 2021;271:105638.
Article
CAS
PubMed
Google Scholar
Paltrinieri S, Gradoni L, Roura X, Zatelli A, Zini E. Laboratory tests for diagnosing and monitoring canine leishmaniasis. Vet Clin Pathol. 2016;45:552–78.
Article
PubMed
Google Scholar
Lopez R, Lucenà R, Novahls M, Ginel PJ, Martin E, Molleda JM. Circulating immune complexes and renal function in canine leishmaniasis. J Vet Med B. 1996;43:469–74.
Article
CAS
Google Scholar
Bonfanti U, Zini E, Minetti E, Zatelli A. Free light-chain proteinuria and normal renal histopathology and function in 11 dogs exposed to Leishmania infantum, Ehrlichia canis, and Babesia canis. J Vet Intern Med. 2004;18:618–24.
Article
PubMed
Google Scholar
Acierno MJ, Brown S, Coleman AE, Jepson RE, Papich M, Stepien RL, et al. ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018;32:1803–22.
Article
PubMed
PubMed Central
Google Scholar
Rossi G, Giordano A, Breda S, Lisi C, Roura X, Zatelli A, et al. Big-endothelin 1 (big ET-1) and homocysteine in the serum of dogs with chronic kidney disease. Vet J. 2013;198:109–15.
Article
CAS
PubMed
Google Scholar
IRIS Canine GN Study Subgroup on Immunosuppressive Therapy Absent a Pathologic Diagnosis, Pressler B, Vaden S, Gerber B, Langston C, Polzin D. Consensus guidelines for immunosuppressive treatment of dogs with glomerular disease absent a pathologic diagnosis. J Vet Intern Med. 2013;27(Suppl. 1):S55–9.
IRIS Glomerular Disease Study Group, Goldstein RE, Brovida C, Fernández-Del Palacio ML, Littman MP, Polzin DJ, et al. Consensus recommendations for treatment for dogs with serology positive glomerular disease. J Vet Intern Med. 2013:27(Suppl. 1):S60–6.